BOULDER, Colo., April 27, 2015 /PRNewswire/ -- Array BioPharma
Inc. (Nasdaq: ARRY) will report financial results for the
third quarter of fiscal 2015 and hold a conference call to discuss
those results on Monday, May 4,
2015. Ron Squarer, Chief Executive Officer will lead the
call.
|
Date:
|
Monday, May 4,
2015
|
|
Time:
|
9:00 a.m. Eastern
Time
|
|
Toll-Free:
|
(844)
464-3927
|
|
Toll:
|
(765)
507-2598
|
|
Pass
Code:
|
5249676
|
Webcast, including Replay and Conference Call
Slides:
http://edge.media-server.com/m/p/8tsxszuw/lan/en
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Six Phase 3 studies are
currently enrolling patients. These programs include three cancer
drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 /
wholly-owned) and selumetinib (AstraZeneca). For more
information on Array, please go to www.arraybiopharma.com.
|
CONTACT:
|
Tricia
Haugeto
|
|
Array BioPharma
Inc.
|
|
(303)
386-1193
|
|
thaugeto@arraybiopharma.com
|
Logo -
http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2015-on-may-4-2015-300072840.html
SOURCE Array BioPharma Inc.